by Lucy Prior | Jan 18, 2023 | Press Releases, Welcome
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display...
by Philippa Shelton | Nov 7, 2022 | Welcome
PEGS 2022: Isogenica showcases plans for implementing machine learning tools Isogenica is attending PEGS Europe: Protein and Antibody Engineering Summit, 14-16th November 2022 Isogenica is delighted to announce we’re attending PEGS Europe 2022. ...
by Philippa Shelton | Nov 4, 2022 | Welcome
Isogenica VHH antibodies used in potential therapy for heart failure Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for...
by Philippa Shelton | Nov 4, 2022 | Press Releases, Welcome
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics Announcing a new collaboration with the Frederick National Laboratory for Cancer Research UK-based antibody engineering experts Isogenica are proud... by Philippa Shelton | Jul 12, 2022 | Welcome
Accelerating antibody discovery with machine learning A collaboration with the University of Nottingham and Aston University Advances in computing and data science, such as machine learning (ML) and artificial intelligence (AI), are transforming all aspects of... by Philippa Shelton | Jul 12, 2022 | Welcome
Creating the next generation of immunotherapies with the University of Leicester Isogenica visiting the team at the University of Leicester Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to...